Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hemangiosarcoma 1

Interventions

pembrolizumab 3durvalumab 3Paclitaxel 3Doxorubicin 3Standard of Care 2Nivolumab 2Ipilimumab 2Ifosfamide 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1sarilumab 1regorafenib 1pexidartinib 1pertuzumab 1peginterferon alfa-2a 1pazopanib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × peginterferon alfa-2a × 1 year × Clear all
NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡